| 低氧诱导因子-1的病理生理及相关药物研究进展 |
| 投稿时间：2013-03-19 修订日期：2013-10-18 点此下载全文 |
| 引用本文：冯世杰,马秀娟,宗英,毛煜,张晓冬,弓雪莲,张晓芳,陆国才.低氧诱导因子-1的病理生理及相关药物研究进展[J].药学实践杂志,2014,32(3):161~166 |
| 摘要点击次数: 1142 |
| 全文下载次数: 72 |
|
| 基金项目:科技部重大专项"重大新药创制"(2010ZXG0900X-005),上海市公共卫生重点实验室建设计划(12GWZX0501). |
|
| 中文摘要:低氧诱导因子-1(hypoxia-inducible factors, HIF-1)是介导哺乳动物和人体细胞低氧适应性反应的主要核转录因子,是专一调节氧稳态的关键物质。HIF-1对胚胎的正常发育,软骨及骨的形成等多种生理过程起保护及促进作用,也与肿瘤、糖尿病及其并发症等多种缺血低氧性疾病密切相关。HIF-1在这些疾病中的分子机制已成为目前的研究热点,笔者就HIF-1的结构特征、调控机制、生物学效用及在药物研发等方面进行综述。 |
| 中文关键词:低氧诱导因子-1 低氧反应原件 氧稳态平衡 活性调节 抑制剂 |
| |
| Progress in pathophysiology and related drug development of hypoxia-inducible factor-1 |
|
|
| Abstract:Hypoxia-inducible factor-1 (HIF-1) is a critical nuclear transcriptional factor mediating cell adaptive response to hypoxia in mammalian and human. It is the key mediator which modulates oxygen homeostasis exclusively. In the one hand, HIF-1 can protect and promote kinds of physiological processes, such as embryo normal development, cartilage and bone formation. In the other hand, it is also involved in lots of human deceases which is caused by ischemia and hypoxia, such as tumor, diabetes and its complications. The molecular mechanisms of HIF-1 involved in these diseases have become a research hotspot and such studies will provide the new therapeutic means for these diseases, recent new drug researches have been focused on HIF-1 related signal pathway inhibitors, HIF-1 activity inhibitors, HIF-1 targeted therapy, etc. |
| keywords:hypoxia-inducible factor-1 hypoxia-response element oxygen homeostasis activity regulation inhibitor |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
| 关闭 |
|
|
|
